Minneapolis Heart Institute Foundation

Advanced Heart Failure Research

March 2026 Bi-Annual Update

View as Webpage

Impact with National & International Reach

Fall 2025 & Spring 2026 Conference Contributions

20+ Presentations, Abstracts, and Moderated Sessions

Study Spotlight: FASTR ll

Description

Fluid management of acute decompensated heart failure subjects treated with the Reprieve System

Enrolling Patients with:

Diagnosis of HF with expected hospitalization ≥24 hours, ≥1 worsening symptom and ≥2 physical exam, lab, or invasive findings of HF & receiving or plans to receive HF-specific treatment
≥10 lb above dry weight
Elevated risk of diuretic resistance
Current outpatient prescription for daily loop diuretic
Patient ≥22 years

Principal Investigator:

Dr. David Miranda

Contact:

Mo Reza, RN

Mohammed.reza@allina.com

Recruiting Studies

Surgical & VAD

Studies

Description

PI & Enrolling Sites

INNOVATE

BrioHealth Solutions

Safety and efficacy of the BrioVAD System vs. HeartMate 3 Left Ventricular Assist System

Dr. Benjamin Sun

ANW

TEAM-HF

Abbott

Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure

Dr. Mosi Bennett

ANW

Interventional Heart Failure

ALLAY-HF

Alleviant Medical

No-implant interarterial shunt in patients with HFpEF

Dr. Peter Eckman

ANW & United

ALLAY-HFrEF

Alleviant Medical

No-implant interarterial shunt in patients with HFrEF

Dr. Peter Eckman

ANW

CorCinch-HF

Ancora Heart

AccuCinch Ventricular Restoration System in patients with HFrEF

Dr. Peter Eckman

ANW

Acute Inpatient

FASTR ll

Reprieve Cardiovascular

Fluid management of acute decompensated heart failure subjects treated with Reprieve System

Dr. David Miranda

ANW

Outpatient & Drug

REDEFINE-HF

Colorado Prevention Center

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

Dr. Mosi Bennett

ANW

Electrophysiology

AIM HIGHer

Impulse Dynamics

Cardiac contractility modulation in HFpEF

Dr. Mike Samara

ANW

Peripartum

REBIRTH

U of Pittsburgh / NIH

Impact of bromocriptine on clinical outcomes for peripartum cardiomyopathy

Dr. Retu Saxena

ANW

Observational

NIVA

NIH

Observational study to compare non-invasive venous waveform analysis for heart failure with PCWP during cardiac catheterization

Dr. Nick Haglund

ANW

OHP Registry ll

Transmedics

Clinical outcomes of heart transplant recipients that used the Organ Care Heart Perfusion System

Dr. Benjamin Sun

ANW

Pipeline Studies

BENEFIT-HF

CVRx

Barostim-Enabled Nurohormonal Intervention For Improving Treatment of Heart Failure

Dr. Mosi Bennett

ANW

ENHANCE OCS

Transmedics

Enhancing Heart Allograft Function With the OCS Heart System Trial

Dr. Benjamin Sun

ANW

INTeGRATE

Abiomed, J&J

Initiation and titration of GDMT in HF cardiogenic shock with Impella 5.5 for cardiac recovery

Dr. Kasia Hryniewicz

ANW

OASIS-AMICS

Abiomed, J&J

Assessment of Support With Impella® Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Dr. Kasia Hryniewicz

ANW

ANW=Abbott Northwestern; GDMT=Guideline-Directed Medical Therapy; HF=Heart Failure; HFpEF=Heart Failure with Preserved Ejection Fraction; HFrEF=Heart Failure with Reduced Ejection Fraction; ICD=Implantable Cardioverter-Defibrillator; J&J=Johnson & Johnson; LVAD=Left Ventricular Assist Device; NIH=National Institutes of Health; NYHA=New York Heart Association; OHP=Organ Care Heart; OCS=Organ Care System; Perfusion System; PCWP=Pulmonary Capillary Wedge Pressure; PI=Principal Investigator; VAD=Ventricular Assist Device

For more information, please contact Julianne Feola
at julianne.Feola@allina.com; Ph: (585)944-8268

Interested in clinical trials from our other areas of cardiovascular research? Visit mplsheart.org/archive for any recent emails you may have missed.